A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease.

Next Previous
Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GEMINI-II
  • Sponsors Millennium

    • Most Recent Events

    • 16 Oct 2017 According to a Takeda media release, post-hoc analysis from this trial will be presented at the World Congress of Gastroenterology (WCOG) at ACG2017.
    • 10 Jun 2017 Biomarkers information updated
    • 08 May 2017 According to a Takeda Pharmaceutical media release, results of post-hoc analysis of GEMINI-1 and GEMINI-II presented at he 2017 Digestive Disease Week (DDW) annual scientific meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top